Stéphane Bancel, Moderna CEO (Markus Schreiber/AP Images)

Mod­er­na touts broad­er an­ti­body da­ta on up­dat­ed Covid vac­cine as it gears up for fall roll­out

As Mod­er­na awaits an FDA de­ci­sion to kick-start its fall Covid vac­ci­na­tion cam­paign, the biotech is con­tin­u­ing to beef up its da­ta pack­age.

Mod­er­na re­port­ed new clin­i­cal tri­al da­ta Wednes­day sug­gest­ing that its up­dat­ed Covid-19 vac­cine gen­er­ates neu­tral­iz­ing an­ti­bod­ies against BA.2.86, or Piro­la, a vari­ant that is be­ing mon­i­tored. Based on a re­search as­say, the jab led to an 8.7-fold in­crease in an­ti­bod­ies against this spe­cif­ic vari­ant. BA.2.86 is a high­ly mu­tat­ed vari­ant, ac­cord­ing to the com­pa­ny, which the CDC has not­ed “may be more like­ly to break through ex­ist­ing im­mu­ni­ty from pre­vi­ous vac­ci­na­tion or in­fec­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.